Purple Biotech (Israel) Today
| KTOV Stock | ILA 5.90 0.30 4.84% |
Performance4 of 100
| Odds Of DistressOver 67
|
Purple Biotech is trading at 5.90 as of the 31st of January 2025, a 4.84 percent decrease since the beginning of the trading day. The stock's open price was 6.2. Purple Biotech has more than 67 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 11th of February 2023 and ending today, the 31st of January 2025. Click here to learn more.
Kitov Pharma Ltd, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. The company has 172.11 M outstanding shares. More on Purple Biotech
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Purple Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Purple Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Purple Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Itzhak Israel |
| Thematic Idea | IT (View all Themes) |
| Business Concentration | IT, Health Care, Pharmaceuticals, Biotechnology, Healthcare, Computing (View all Sectors) |
Purple Biotech (KTOV) is traded on Tel Aviv Stock Exchange in Israel and employs 9 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 227.01 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Purple Biotech's market, we take the total number of its shares issued and multiply it by Purple Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Purple Biotech operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 172.11 M outstanding shares.
Purple Biotech has accumulated about 63.01 M in cash with (5.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.4.
Check Purple Biotech Probability Of Bankruptcy
Ownership AllocationPurple Biotech owns a total of 172.11 Million outstanding shares. Roughly 98.66 pct. of Purple Biotech outstanding shares are held by general public with 0.12 % owned by insiders and only 1.22 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Purple Ownership Details
Purple Biotech Risk Profiles
Although Purple Biotech's alpha and beta are two of the key measurements used to evaluate Purple Biotech's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 6.56 | |||
| Standard Deviation | 13.44 | |||
| Variance | 180.72 | |||
| Risk Adjusted Performance | (0.01) |
Purple Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Purple Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Correlation Analysis Now
Correlation AnalysisReduce portfolio risk simply by holding instruments which are not perfectly correlated |
| All Next | Launch Module |
Purple Biotech Corporate Directors
| Steven Steinberg | Independent Director | Profile | |
| Arie Weber | Independent Director | Profile | |
| Ran Tzror | Independent Director | Profile | |
| Simcha Rock | CFO, Director | Profile |
Additional Information and Resources on Investing in Purple Stock
When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.